A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

MORE than half of adults living with type 1 diabetes believe the condition stops them from being more spontaneous. A poll of ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

A recent survey found that more than half of adults living with Type 1 diabetes believe the condition limits their ability to be spontaneous ...

The second patient, a 64-year-old woman who required supplemental insulin injections because leptin alone couldn't control her blood glucose, achieved normal blood glucose levels with tirzepatide ...

A recent survey found that more than half of people living with Type 1 diabetes say the condition has an impact on their ...

A weekly diabetes medication may replace painful daily hormone injections for patients with congenital generalised lipodystrophy (CGL). Early findings suggest that tirzepatide – used for diabetes and ...

A new survey has found that Type 1 diabetes can affect everyday decisions for nearly a third of those diagnosed ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).